On the stock market since 2009, it operates in the world of health and science. It has 94,300 employees. Now — the numbers.
This is an established company with proven profits.
Revenue is spread across several lines; no single product carries the company.
Average growth of 12% a year over the last 4 years. Every year shown ended in profit.
The gap is $23.9B. In times of high interest rates, a gap like that can squeeze a company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
The stock trades below its recent peak — about 9% off the top. A pullback, not a collapse.
The net profit margin is 17% — still a thick cushion, though costs have been eating into it lately.
Over the last 3 years, sales grew about 10% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
The price action doesn’t yet back an upward turn. Council score: 0/10.
On our five-subject report card, AZNCF sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: AZNCF is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.